Generation Bio(GBIO) - 2024 Q3 - Quarterly Results

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results ● Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) ● Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Nov. 6, 2024 -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and t ...